The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland
Authors:
- Alekh ThapaATAlekh Thapa
- Anna CowellACAnna Cowell
- Adam PetersAPAdam Peters
- David J NobleDNDavid J Noble
- Allan JamesAJAllan James
- Carolynn LambCLCarolynn Lamb
- Derek GroseDGDerek Grose
- Saurabh VohraSVSaurabh Vohra
- Stefano SchipaniSSStefano Schipani
- Karen MactierKMKaren Mactier
- Joanna MackenzieJMJoanna Mackenzie
- Devraj SrinivasanDSDevraj Srinivasan
Preprint
Abstract
Objectives: The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence who approved monotherapy alone in England and Wales. We aimed to provide real-world performance data for first-line pembrolizumab-containing treatments for head and neck squamous cell carcinoma (HNSCC) in the palliative setting in Scotland. Materials and Methods: We analysed the electronic records of patients who initiated pembrolizumab-containing treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free survival (PFS), duration of response (DOR), disease control rate (DCR). Data were compared with the KEYNOTE-048 study and clinical factors were evaluated for association with survival. Results: Our cohort included 91 patients (median follow-up 10.8 months). Patient characteristics were similar to the KEYNOTE-048 study though our cohort had a higher proportion of patients with newly diagnosed, non-metastatic disease. For patients receiving monotherapy (n=76), 12-month and 24-month OS was 45% and 27%, respectively. For patients receiving pembrolizumab-chemotherapy (n=15), 12-month OS was 60% (24-month OS had not yet been reached). Experiencing ≥1 irAE (versus no irAEs), of any grade, was associated with favourable OS and PFS for patients receiving monotherapy in both univariable log-rank analysis (median OS 17.4 months versus 8.6 months, respectively, P=0.0033; median PFS 10.9 months versus 3.0 months, respectively, P<0.0001) and multivariable analysis (Cox proportional hazards regression: OS HR: 0.31, P=0.0009; PFS HR: 0.17, P<0.0001). Conclusion: Our real-world data support the KEYNOTE-048 study findings and the value of combination treatment options. Additionally, our data show irAEs of any grade, as reported in routine clinical records, are associated with better outcomes in this patient group, adding to the growing body of evidence showing irAEs are generally a positive marker of PD-L1 inhibitor response.Keywords
All Related Versions
- Published version: Clinical Oncology, 36 (5), 287.
This publication has 28 references indexed in Scilit:
- Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancerCancer Treatment Reviews, 2020
- Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumabOral Oncology, 2020
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre studyActa Oto-Laryngologica, 2019
- Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancerCancer, 2019
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysisJournal of Cancer Research and Clinical Oncology, 2018
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerJAMA Oncology, 2018
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) StatementPLOS Medicine, 2015